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Abstract
The inoculum effect is a laboratory phenomenon in which the minimal inhibitory concentration (MIC) of an antibiotic is increased when a
large number of organisms are exposed. Due to the emergence of extended-spectrum b-lactamase-producing Klebsiella pneumoniae
(ESBL-Kpn) infections, the inoculum effect of ESBL-Kpn on b-lactams was studied in vitro and in vivo using an experimental model of
pneumonia. The in vitro inoculum effect of 45 clinical ESBL-Kpn isolates on b-lactams was evaluated at standard (105 CFU/mL) and high
(107 CFU/mL) organism concentrations. The MIC50 of piperacillin-tazobactam, cefotaxime and cefepime was increased eight-fold or more
and that of meropenem was increased two-fold. The in vivo inoculum effect was evaluated in an ESBL-Kpn pneumonia mouse model treated
with bacteriostatic effect-adjusted doses of piperacillin-tazobactam (1000 mg/kg four times daily, %T > MIC; 32.60%) or meropenem
(100 mg/kg twice daily, %T > MIC; 28.65%) at low/standard (104 CFU/mouse) and high (106 CFU/mouse) inocula. In mice administered a
low inoculum, no mice died after treatment with piperacillin-tazobactam or meropenem, whereas all the control mice died. In contrast, in
the high inoculum model, all mice in the piperacillin-tazobactam-treated group died, whereas all meropenem-treated mice survived and had
a decreased bacterial load in the lungs and no invasion into the blood. In conclusion, meropenem was more resistant to the inoculum effect
of ESBL-Kpn than piperacillin-tazobactam both in vitro and in vivo. In the management of severe pneumonia caused by ESBL-Kpn,
carbapenems may be the drugs of choice to achieve a successful outcome.
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Introduction
The emergence of extended-spectrum b-lactamase
(ESBL)-producing organisms, particularly Escherichia coli and
Klebsiella pneumoniae, has been a major clinical concern.
Because broad-spectrum penicillins and cephalosporins are
often not effective against ESBL-producers, selecting the
appropriate therapy for treatment of serious infections due
to ESBL producers is a challenge. In fact, the mortality rate is
reportedly higher when the causative bacteria produce ESBL
or when the patients received inadequate therapy against ESBL
producers [1–3]. Klebsiella pneumoniae pneumonia is often
characterized by a rapid clinical course, leading to widespread
systemic effects and death [3–5]. Because K. pneumoniae
infections are commonly hospital or healthcare associated
and primarily occur in patients with impaired host defences
due to diabetes mellitus or alcoholism [4,5], these infections
sometimes becomes severe.
The recommended inoculum size for antimicrobial suscep-
tibility testing based on the broth dilution method is c.
5 9 105 CFU/mL [6]. However, the in vitro effect of antibiotics
is known to depend on the number of bacteria exposed [7,8].
The inoculum effect is a laboratory phenomenon in which the
minimal inhibitory concentration (MIC) of an antibiotic is
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signiﬁcantly increased when the number of organisms in the
inoculum is increased [9]. The inoculum effect has been
observed for b-lactams against b-lactamase-producing bacteria
[10,11]. However, the clinical signiﬁcance of this laboratory
phenomenon has yet to be elucidated.
Therefore, strategies for successful treatment of pulmonary
infections as well as bacteraemia due to ESBL-producing
K. pneumoniae should be investigated [12]. In clinical settings,
piperacillin-tazobactam and carbapenems have been widely
used to treat patients with infections caused by ESBL
producers. However, the therapeutic efﬁcacy of piperacil-
lin-tazobactam for patients with infections due to ESBL
producers is controversial [13,14], whereas carbapenems
produce favourable outcomes [1]. The in vitro activity of
piperacillin-tazobactam has been called into question because
of the substantial inoculum effect observed in dilution suscep-
tibility tests using ESBL producers [15–17]. Although many
studies about the in vitro inoculum effect on b-lactams have
been reported [16,18,19], in vivo reports are limited. In a blood
stream infection model with ESBL-producing E. coli, the high
inoculum group showed piperacillin-tazobactam treatment
failure [20]. In contrast, in a thigh infection model, carbapen-
ems showed potent activity against ESBL-producing E. coli and
K. pneumoniae [21]. To determine the efﬁcacy of b-lactams in
pulmonary infections caused by ESBL-producing K. pneumo-
niae, an in vivo study is required.
In this study, the in vitro activity of b-lactams against
ESBL-K. pneumoniae clinical isolates was evaluated at the
standard and high inocula. In addition, the in vivo efﬁcacies of
meropenem and piperacillin-tazobactam were studied in a
mouse model of pulmonary infection with different inoculum
sizes of ESBL-producing K. pneumoniae.
Materials and Methods
Collection of clinical isolates
ESBL-producing K. pneumoniae isolates were collected from
patients at Nagasaki University Hospital during the period
from January 2004 to December 2011. When several isolates
were detected in a sample from the same patient, only one
isolate was selected. A total of 45 isolates were analysed in this
study.
Antibiotic susceptibility testing
Antibiotic susceptibility was determined using the broth
microdilution method for penicillin, piperacillin-tazobactam,
ceftazidime, cefotaxime, cefepime, cefpodoxime and merope-
nem according to the procedures outlined by Clinical and
Laboratory Standards Institute (CLSI) [6]. Two different
concentrations of bacteria were inoculated, the low/standard
inoculum (1–5 9 105 CFU/mL) and high inoculum
(1–5 9 107 CFU/mL).
Genotyping of ESBL
Plasmids were extracted from the bacteria by heat lysis as
described previously [22]. For detecting ESBL genes, TEM,
SHV and three CTX-M groups (CTX-M-1, CTX-M-2 and
CTX-M-9) were targeted and each gene was ampliﬁed by
polymerase chain reaction (PCR) [22]. The PCR products
were analysed using 2% agarose gel electrophoresis and
visualized by staining with ethidium bromide.
Time-kill assays
The bacteria were inoculated into 100 lL of Mueller-Hinton
broth in a 96-well plate at the standard (1–5 9 105 CFU/mL)
and high (1–5 9 107 CFU/mL) concentrations. Piperacillin-ta-
zobactam or meropenem were added at concentrations of 19
and 169 MIC (for each strain) or 19, 49 and 169 MIC (for
the experimental strain). After incubation with antibiotics at
37°C for 24 and 48 h, the bacteria were serially diluted and
plated on Mueller-Hinton II broth agar plates. The visible
colonies on the plates were counted.
Animals
Male, 6- to 8-week-old BALB/c mice were purchased from
Japan SLC, Inc. (Shizuoka, Japan). All animals were housed in a
pathogen-free environment in the Laboratory Animal Center
for Biomedical Science at Nagasaki University and were
provided sterile food and water. The Ethics Review Commit-
tee for Animal Experimentation approved all experimental
protocols used in this study.
Pharmacokinetic studies
Mice were treated with piperacillin (100 mg/kg) in combina-
tion with tazobactam (12.5 mg/kg) or with meropenem
(100 mg/kg) in combination with cilastatin (100 mg/kg), a
DHP-1 inhibitor. The plasma was separated by centrifugation
and the isolated plasma of the meropenem-treated group was
mixed with one-half volume of (N-morpholino)-propanesulf-
onic acid (MOPS) buffer (pH 5.5) for the purpose of
stabilization of meropenem.
The level of biologically active b-lactams in plasma was
determined by the bioassay method with Micrococcus luteus
ATCC9341 for piperacillin or with E. coli NIHJ for merope-
nem as the indicator organism. Standard curves were made
for the antibiotics in pooled mouse plasma. The disk diffusion
bioassay was performed in triplicate with 50 lL of plasma
from b-lactam-administered mice by using 8-mm-diameter
paper disks (cat. no. 49005010; Advantec, Tokyo, Japan). The
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lower limits of detection of piperacillin and meropenem were
0.5 and 0.06 lg/mL, respectively. The intra- and interday
variations of both drugs were <15%. The pharmacokinetic
parameters were calculated using a two-compartment model
with the MULTI program [23]. The percentage of time that
free-drug concentrations above the MIC was calculated using
pharmacokinetic parameters, murine protein binding (10%)
[24,25] and MICs.
Preparation of bacteria and the mouse model of pulmonary
infection
Klebsiella pneumoniae, KEN-11 strain (positive for SHV and
CTX-M-9 type ESBLs and positive for the string test [25,26]),
was used. The MICs of piperacillin-tazobactam and merope-
nem were 1.0 and 0.015 lg/mL, respectively. When evaluated
at the high inoculum, the MICs of piperacillin-tazobactam and
meropenem were 256 and 0.12 lg/mL, respectively. The
bacteria were stored at 80°C in a Microbank system
(Pro-Lab Diagnostics, Ontario, Canada) until use.
To prepare inocula, a single colony of KEN-11 was
preincubated in Luria-Bertani (LB) broth [26] containing
100 lg/mL penicillin at 37°C for 18 h with shaking at
250 rpm. After 8 h of additional incubation in fresh LB broth,
the bacteria were adjusted to appropriate concentrations by
turbidimetry. Mice were intratracheally infected with bacterial
suspension (50 lL/mouse) under pentobarbital anaesthesia
(40 mg/kg delivered by intraperitoneal injection).
Treatment protocol
Meropenem and piperacillin-tazobactam were used for the in
vivo study. Meropenem was used in combination with the same
dose of cilastatin because carbapenems are hydrolyzed by
murine DHP-1 [27]. The in vivo efﬁcacy of the pharmacoki-
netically-adjusted treatment protocol was evaluated in the low
(1 9 104 CFU/mouse) and high (1 9 106 CFU/mouse) inoc-
ula models.
Treatment commenced 12 h after inoculation. Mice were
treated four times a day with the same volume of the agents or
saline. The mice were observed for up to 5 days after
inoculation.
Bacteriological and histopathological examination
Mice were sacriﬁced at 36 and 84 h after inoculation. Blood
was collected by right ventricular puncture using hepa-
rin-coated syringes. Aseptically-dissected lungs were homog-
enized using a homogenizer (AS One Co., Osaka, Japan). After
culture of serially-diluted lung specimen on the Mueller-Hinton
II agar, the visible colonies were counted. For the histopath-
ological examination, the lung specimen was ﬁxed in 10%
buffered formalin, and the parafﬁn-embedded sections were
stained with hematoxylin-eosin.
Analysis of bronchoalveolar lavage ﬂuid
After the pulmonary vasculature was ﬂushed with 3 mL of
normal saline via the right ventricle, lungs were lavaged three
times with 1 mL of normal saline as described previously [28].
Statistical analysis
Survival data are presented as Kaplan–Meier curves. The data
are expressed as the mean  standard errors of the mean
(SEM). Differences between the groups were analysed using
Tukey’s post-test followed by the Kruskal–Wallis non-para-
metric test. A p value of <0.05 was considered statistically
signiﬁcant.
Results
In vitro inoculum effects of ESBL-producing Klebsiella
pneumoniae clinical isolates on b-lactams
We tested the susceptibilities of the clinical strains to seven
b-lactams at low/standard and high inocula. A summary of
ESBL genotypes is shown in Table 1. MIC shifting was
observed for all agents and a greater than eight-fold increase
in MIC50 was observed for tazobactam-piperacillin, cefotaxime
and cefepime (Table 2).
Time-kill study of ESBL-Klebsiella pneumoniae clinical isolates
Time-kill studies were performed at different drug concentra-
tions. Of the 45 clinical strains, 21 were within themeasurement
range and were veriﬁable. At the standard inoculum, 19 MIC
piperacillin-tazobactam did not decrease the number of viable
bacteria, whereas the other conditions showed ≥3 log decreases
after 24 h (169MIC piperacillin-tazobactam, 4.0  0.6 log; 19
MIC meropenem, 3.8  0.5 log; 169 MIC meropenem,
TABLE 1. Genotypes of ESBL-producing Klebsiella pneumo-
niae
Genotype(s) Number of the isolates
TEM 1
SHV 16
CTX-M-9 1
TEM + SHV 6
TEM + CTX-M-9 2
SHV + CTX-M-1 1
SHV + CTX-M-2 4
SHV + CTX-M-9 4
TEM + SHV + CTX-M-1 4
TEM + SHV + CTX-M-9 3
Not detected 3
Total 45
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O831–O839
CMI Harada et al. Innoculum effects on ESBL-K. pneumoniae O833
4.9  0.1 log) (Fig. 1a). Similarly, at the high inoculum, veriﬁed
conditions except for 19 MIC piperacillin-tazobactam
decreased the number of viable bacteria (Fig. 1b). The sizes of
the decreases after treatment with 169 MIC piperacillin-tazo-
bactam and 19 and 169 MIC meropenem were 3.1  0.6,
3.0  0.5 and 6.8  0.2 log, respectively.
Selection of an ESBL-producing Klebsiella pneumoniae strain
for the pneumonia model
The clinical isolates were prescreened for an in vivo experi-
ment. Of the seven randomly selected isolates, only the
KEN-11 strain was pneumotropic. KEN-11 was able to adapt
to the mouse lung and consistently caused pneumonia. In vitro,
a standard inoculum of KEN-11 was suppressed by antibiotics,
except for 19 MIC piperacillin-tazobactam (Fig. 2a), but a high
inoculum of KEN-11 was suppressed only by meropenem in a
dose-dependent manner (Fig. 2b).
The percentage of time above MIC (%T > MIC) that is
required for bacteriostatic effects is 30–35% for penicillins [29]
and 25–40% for carbapenems [30]. On the basis of pharma-
cokinetic analysis (Fig. 3), the dose of each agent was designed
to exceed the bacteriostatic %T > MIC for the pathogen
(piperacillin-tazobactam, 1000 mg/kg four times daily; merope-
nem, 100 mg/kg twice daily; Table 3).
In vivo study of different inoculum sizes
In the low inoculum model, all control mice died by 120 h,
whereas all mice treated with antibiotics survived during the
entire experimental period (n = 7, p <0.01 vs. the control,
Fig. 4a). Next, the bacterial load in the lungs (Fig. 4b) and
blood (Fig. 4c) was examined in the early (36 h) and late (84 h)
phase of infection. Compared with the control group, the
number of bacteria in mice of the piperacillin-tazobactam and
meropenem-treated group was decreased. Bacteria were
observed also in the blood of mice in the control group,
whereas no bacteria were observed in the blood of mice in the
other groups, except for two mice in the piperacillin-tazobac-
tam group in the early phase.
In the high inoculum model, all mice in the control and
piperacillin-tazobactam-treated groups died, whereas all mice
in the meropenem-treated group survived for the entire
experimental period (p <0.01, vs. the control and piperacil-
TABLE 2. MICs of various antimicrobial agents against ESBL-producing Klebsiella pneumoniae clinical isolates at different
inoculum sizes
Antimicrobial agent Evaluated range
MIC50 MIC90
SI (lg/mL) HI (lg/mL) MIC shift (HI/SI) SI (lg/mL) HI (lg/mL) MIC shift (HI/SI)
Piperacillin <64 to >1024 512 >1024 >2 >1024 >1024
Piperacillin-tazobactam <1 to >1024 16 256 16 >1024 >1024
Ceftazidime <2 to >512 8 16 2 256 512 2
Cefotaxime <2 to >512 32 256 8 256 >512 >4
Cefpodoxime <2 to >512 128 256 2 512 >512 >2
Cefepime <1 to >1024 4 256 64 32 >1024 >32
Meropenem <0.015 to >16 0.03 0.06 2 0.12 0.5 4
A summary of 45 clinical isolates. SI, standard inoculum (1–5 9 105 CFU/mL); HI, high inoculum (1–5 9 07 CFU/mL).
(a) (b)
FIG. 1. Time-kill curves of ESBL-producing Klebsiella pneumoniae clinical isolates. Time-kill studies at the standard (a) and high (b) inocula were
performed with different concentrations of piperacillin-tazobactam (ﬁlled circles) and meropenem (open circles) (n = 21). The isolates for which the
MIC was out of measurement range were excluded. The log changes in the number of viable bacteria from the start of the experiment are shown.
The detection limit of the colony count is 100 CFU/mL. When the number of the colony was less than the detection limit, the log change was
considered as the number at the start of the experiment. The solid and dashed lines represent 19 MIC and 169 MIC, respectively. The error bars
represent the standard error of the mean.
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lin-tazobactam-treated groups) (n = 7, Fig. 4d). In the lungs
(Fig. 4e), a signiﬁcant decrease in the number of bacteria was
observed in the early phase in the piperacillin-tazobac-
tam-treated and meropenem-treated groups, compared with
the control group. In the late phase, the surviving mice in the
piperacillin-tazobactam-treated group had a high bacterial load
in their lungs, compared with the meropenem group. In the
blood, no bacteria were observed in the meropenem-treated
mice (Fig. 4f).
Evaluation of the in vivo inﬂammatory ﬁndings in mice with
different inoculum sizes
The severity of lung inﬂammation was evaluated by histopath-
ological examination and cytological analysis of bronchoalveo-
lar lavage ﬂuid (BALF).
In the low inoculum model, an inﬂux of numerous
inﬂammatory cells was observed in the alveoli of the control
group, whereas fewer cells were observed in other groups
(Fig. 5a). The number of neutrophils in BALF was signiﬁcantly
lower in the antibiotic-treated groups than in the control
group (Fig. 5b).
In the high inoculum model, piperacillin-tazobactam and
meropenem suppressed the number of cells in the alveolar
spaces in the early phase, and the levels appeared to be similar
in the late phase (Fig. 5c). Treatment with piperacillin-tazo-
bactam or meropenem signiﬁcantly decreased the number of
neutrophils in BALF compared with the number in the control
group in the early phase (Fig. 5d). In the late phase, the number
of neutrophils in the piperacillin-treated group increased
slightly from that in the early phase.
Discussion
Infections caused by ESBL-producing K. pneumoniae have
become a growing concern. Although their inoculum effect
on b-lactams as an in vitro phenomenon is widely known, the
potential utility of piperacillin-tazobactam and meropenem for
(a) (b)
FIG. 2. Time-kill curves for KEN-11.
Time-kill studies for KEN-11 at the
standard (a) and high (b) inocula were
performed with different concentrations
of piperacillin-tazobactam (ﬁlled circles)
and meropenem (open circles). Solid,
dashed and dotted lines represent 19,
49 and 169 MIC, respectively.
TABLE 3. Pharmacokinetic parameters of piperacillin-tazobactam and meropenem and predicted values for in vivo treatment
settings
Antimicrobial
agent
Selected pharmacokinetic parameters In vivo treatment settings
AUC0–∞
(lgmin/mL) T1/2 (min)
CL
(mL/min/kg)
Vd
(L/kg)
MIC against
KEN-11 (lg/mL)
Dose setting
(mg/kg)
Predicted
T > MIC (h)
Predicted 24 h%T > MIC (%)
Once/day Twice/day
Four
times/day
Piperacillin 3744.6 15.1 26.7 0.59 0.015 100 3.44 14.33 28.65
Meropenem 1423.8 11.9 70.2 1.20 1.0 1000 1.92 8.01 16.03 32.06
AUC, area under the curve; T1/2, elimination half-life; CL, clearance; Vd, volume of distribution.
TZP
MEM
FIG. 3. In vivo pharmacokinetic analysis of piperacillin and merope-
nem. Mouse serum concentrations of piperacillin (ﬁlled circles) and
meropenem (open circles) were measured after intraperitoneal
administration. Meropenem was administrated with the DHP-I inhib-
itor cilastatin. Error bars represent the standard error of the mean.
TZP, piperacillin-tazobactam; MEM, meropenem.
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the treatment of severe pneumonia due to ESBL-producing
K. pneumoniae is not well understood.
In vitro study showed that piperacillin-tazobactam, cefotax-
ime and cefepime have the potential to be easily affected by the
inoculum size of ESBL-producing K. pneumoniae. These ﬁndings
were consistent with previous reports [16,31]. Because the
MIC of cefepime tends to be increased substantially by the
increased number of b-lactamase-producing bacteria [32,33], it
can be ineffective for patients with bacteraemia caused by ESBL
producers [34]. Although meropenem also showed a mild MIC
shift, the shifted MIC of meropenem is still below the tissue
concentration. Therefore, the in vitro results suggest that the
antimicrobial activity of meropenem is stable at infection sites
with high bacterial concentrations.
The activities of b-lactams against ESBL producers can vary
according to ESBL subgroups, such as TEM-, SHV- and
CTX-M-type, and these subgroup ESBLs have different
susceptibilities to piperacillin-tazobactam [35–37]. Our results
were sorted by ESBL subgroup [22]; however, no clear
differences were observed between the subgroups (data not
shown). To evaluate this point, experiments using a greater
number of isolates may be required.
In the time-killing study, meropenem showed potent activity
against the tested isolates but the activity of piperacillin-tazo-
bactam seemed to be weak. This bactericidal activity of
piperacillin-tazobactam was consistent with a previous report
[38]. The inoculum effect on piperacillin-tazobactam has been
shown to be associated with the release of large amounts of
hydrolyzing b-lactamases from lysed bacteria [13].
In vivo, the efﬁcacy of piperacillin-tazobactam was more
sensitive to inoculum size than meropenem. Notably, our
results suggest that the inoculum effect can have an inﬂuence
on the outcome even if the causative strain shows very low
MIC for piperacillin-tazobactam. The in vivo efﬁcacies of
antibiotics for different inoculum sizes have been reported
for some animal models, such a pneutropenic mouse model of
thigh infection [21] and a sepsis model [20]. The results in
these previous reports and our results imply that carbapenems
may be stable in vivo and have potent activities in heavy
bacterial loads at the infection site. However, our results do
not recommend the use of carbapenems against all infections
caused by ESBL-producing K. pneumoniae, because carbape-
nem exposure may promote the selection and colonization of
carbapenem-resistant variants such as Pseudomonas aeruginosa
(a)
(d)
(b)
(e)
(c)
(f)
FIG. 4. Survival and bacteriological examinations from the in vivo study. The inoculum effects were studied in vivo using a mouse model of
pneumonia induced by ESBL-producing Klebsiella pneumoniae at the standard (a, b and c) and high (d, e and f) inocula. Mice were treated with saline
(control, ﬁlled circles), piperacillin-tazobactam (open circles) or meropenem (gray circles) according to the pharmacokinetically-designed treatment
protocol. (a and d) Kaplan–Meier survival curves; *p <0.05 vs. the control, **p <0.01 vs. the control, and †p <0.01 vs. piperacillin-tazobactam.
Microbiological studies in the lungs (b and e) and the blood (c and f); *p <0.05 and **p <0.01. TZP, piperacillin-tazobactam; MEM, meropenem; N/A,
not available.
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and Acinetobacter baumannii [39,40]. In the case of ESBL-pro-
ducing K. pneumoniae infections that are severe or have
responded poorly to piperacillin-tazobactam, carbapenems
can be considered as the drug of ﬁrst choice. To reduce the
risk of the increase of carbapenem-resistant strains, new
combinations of penicillins and novel b-lactamase inhibitors
that are insusceptible to the inoculum effect should be
evaluated in our model.
This study has some limitations. Our in vivo study was
performed with only one strain because the number of
K. pneumoniae isolates carrying ESBL and having afﬁnity for the
mouse lung were limited. From a pharmacokinetic point of view,
it is not clear whether a dose schedule based on human
pharmacokinetics is effective in mice. In addition, the plasma
pharmacokinetics of antimicrobial agents in critically ill patients
can differ substantially from that in clinically stable patients [41].
Therefore, clinical studies are needed to address these issues.
In agreement with the in vitro data, the in vivo efﬁcacy of
meropenem for treating pneumonia due to ESBL-producing
K. pneumoniae was not affected by inoculum size and was
superior to that of piperacillin-tazobactam. In the management
of severe pneumonia caused by ESBL-producing K. pneumoniae,
carbapenems can be the ﬁrst-choice drug for a successful cure.
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FIG. 5. Histopathological and BALF examinations of mice from the in vivo study. Haematoxylin-eosin staining of lung specimens (a and c) and the
number of neutrophils in BALF (b and d) are shown. Experiments were performed using mice administered the standard (a and b) and high (c and d)
inocula. Pathological data are shown for three representative mice in each group. Error bars represent the standard error of the mean. *p <0.05;
TZP, piperacillin-tazobactam; MEM, meropenem; N/A, not available.
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